ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals

BRISBANE, Calif. and SHANGHAI, June 17, 2024 /PRNewswire/ — ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncology indications, and Asieris Pharmaceuticals, a global biopharmaceutical…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks